valproic acid has been researched along with Substance-Related Disorders in 56 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Substance-Related Disorders: Disorders related to substance use or abuse.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To pilot the efficacy and safety data of lamotrigine adjunctive therapy to lithium and divalproex in patients with rapid-cycling bipolar disorder (RCBD) and a recent substance use disorder (SUD)." | 9.14 | Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. ( Calabrese, JR; Chan, PK; Conroy, C; Fang, Y; Findling, RL; Ganocy, SJ; Gao, K; Kemp, DE; Serrano, MB; Wang, Z, 2010) |
| "Resolution of hyperammonemia caused by Valproic acid therapy may be enhanced with the administration of L-carnitine." | 8.95 | Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report. ( Ballabio, M; Cattaneo, CI; D'Innella, P; Fornaro, M; Ressico, F; Valsesia, R, 2017) |
| "We evaluated the occurrence of seizures in 450 consecutive high-dose BZD dependence patients admitted to our unit from April 2012 to April 2016 for detoxification with low-dose slow subcutaneous infusion of flumazenil associated with routine anticonvulsant prophylaxis." | 5.46 | Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence. ( Bongiovanni, LG; Casari, R; Faccini, M; Federico, A; Franchini, E; Lugoboni, F; Morbioli, L; Tamburin, S, 2017) |
| "Side effects of carbamazepine (CBZ), valproate (VPA) and clonazepam (CZP) are rare during long-term use but rather common and usually transient during the early phases of treatment." | 5.27 | Side effects of carbamazepine, valproate and clonazepam during long-term treatment of epilepsy. ( Keränen, T; Sivenius, J, 1983) |
| "To pilot the efficacy and safety data of lamotrigine adjunctive therapy to lithium and divalproex in patients with rapid-cycling bipolar disorder (RCBD) and a recent substance use disorder (SUD)." | 5.14 | Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. ( Calabrese, JR; Chan, PK; Conroy, C; Fang, Y; Findling, RL; Ganocy, SJ; Gao, K; Kemp, DE; Serrano, MB; Wang, Z, 2010) |
| "Overall, the combination of Buprenorphine and Valproate seems to be a safe and promising method for treating multiple drug withdrawal symptoms." | 5.12 | Treatment of polydrug-using opiate dependents during withdrawal: towards a standardisation of treatment. ( Clausen, T; Isaksen, A; Kristensen, Ø; Lølandsmo, T; Vederhus, JK, 2006) |
| "Resolution of hyperammonemia caused by Valproic acid therapy may be enhanced with the administration of L-carnitine." | 4.95 | Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report. ( Ballabio, M; Cattaneo, CI; D'Innella, P; Fornaro, M; Ressico, F; Valsesia, R, 2017) |
| "This 12-month, prospective, observational study investigated factors associated with symptomatic remission (total YMRS score < or =12) and full clinical recovery (sustained reduction in CGI-BP-S overall score) in bipolar disorder during treatment with atypical antipsychotics (predominantly olanzapine, risperidone and quetiapine; alone or in combination with a psychotropic such as lithium or valproate) in actual clinical practice." | 3.76 | Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics. ( Badr, MG; D'yachkova, Y; Dikeos, D; Fábián, Z; Harrison, G; Hudiţă, C; Okasha, T; Pesek, MB; Tapia-Paniagua, G; Treuer, T; Yang, F, 2010) |
| "Valproate may have greater acceptability than lithium among patients with bipolar disorder and substance use disorder." | 3.70 | Medication compliance among patients with bipolar disorder and substance use disorder. ( Greenfield, SF; Griffin, ML; Najavits, LM; Soto, JA; Tohen, M; Weiss, RD; Wyner, D, 1998) |
| "A case of severe valproic acid poisoning with coma and insufficient respiration is reported." | 3.67 | Electroencephalographic alterations during intoxication with sodium valproate: a case report. ( Juul-Jensen, P; Pedersen, B, 1984) |
| "Past substance abuse was evident in 34% of the bipolar sample and comprised most often alcoholism (82%), followed by cocaine (30%), marijuana (29%), sedative-hypnotic or amphetamine (21%), and opiate (13%) abuse." | 2.69 | A history of substance abuse complicates remission from acute mania in bipolar disorder. ( Garno, JL; Goldberg, JF; Kocsis, JH; Leon, AC; Portera, L, 1999) |
| "Substance abuse is a common comorbid illness in patients with mood disorders." | 2.69 | Divalproex sodium in substance abusers with mood disorder. ( Albanese, MJ; Clodfelter, RC; Khantzian, EJ, 2000) |
| "In this preliminary report from a placebo-controlled, double-blind, dose-response study on the use of pergolide mesylate for cocaine dependence in outpatients 8 out of 235 subjects noted adverse events requiring breaking of the blind." | 2.68 | Pergolide mesylate. Adverse events occurring in the treatment of cocaine dependence. ( Cochrane, CE; Kajdasz, DK; Malcolm, R; Moore, JW, 1997) |
| "Flumazenil treatment can improve with - drawal symptoms and leads to higher abstinence rates." | 2.52 | The problems of long-term treatment with benzodiazepines and related substances. ( Hoffmann, K; Janhsen, K; Roser, P, 2015) |
| "The significant prevalence of substance use disorders among patients with psychiatric illnesses has attracted increasing interest." | 2.39 | The relationship between substance abuse and bipolar disorder. ( Brady, KT; Sonne, SC, 1995) |
| "We evaluated the occurrence of seizures in 450 consecutive high-dose BZD dependence patients admitted to our unit from April 2012 to April 2016 for detoxification with low-dose slow subcutaneous infusion of flumazenil associated with routine anticonvulsant prophylaxis." | 1.46 | Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence. ( Bongiovanni, LG; Casari, R; Faccini, M; Federico, A; Franchini, E; Lugoboni, F; Morbioli, L; Tamburin, S, 2017) |
| "Lamotrigine (LTG) was less successful in those with a parental history of mood disorders or in BP-I compared to BP-II disorder." | 1.43 | Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder. ( Altshuler, LL; Frye, MA; Grunze, H; Keck, PE; Kupka, R; Leverich, GS; McElroy, SL; Nolen, WA; Post, RM; Rowe, M; Suppes, T, 2016) |
| "In recent decades the pattern of substance use among patients admitted for detoxification has changed from predominantly single-substance use to simultaneous multi-substance use." | 1.43 | Standardised detoxification in cases of polydrug use. ( Clausen, T; Dunsæd, F; Høie, MM; Kristensen, Ø; Vederhus, JK, 2016) |
| "Co-morbid substance abuse was uncommon." | 1.39 | Prevalence and clinical presentation of HIV positive female psychiatric inpatients. ( Uys, H, 2013) |
| "In this context, the focal seizures probably result from a diffuse decrease in the seizure threshold (caused by a generalized excitatory rebound), which may trigger focal seizures arising from cortical regions with higher intrinsic epileptogenicity." | 1.38 | Focal nonconvulsive seizures during detoxification for benzodiazepine abuse. ( Albiero, A; Bongiovanni, LG; Brigo, F; Casari, R; Faccini, M; Fiaschi, A; Lugoboni, F; Quaglio, G; Storti, M, 2012) |
| "The effect of comorbid substance use on the likelihood of response differed significantly according to baseline BMI." | 1.36 | Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. ( Calabrese, JR; Chan, PK; Findling, RL; Ganocy, SJ; Gao, K; Kemp, DE, 2010) |
| "Rapid cycling with co-occurring substance use is not only associated with poor response to mood stabilizers, but is also a harbinger of serious medical problems." | 1.35 | Medical and substance use comorbidity in bipolar disorder. ( Bilali, S; Calabrese, JR; Caldes, E; Chan, PK; Conroy, C; Feldman, K; Findling, RL; Ganocy, SJ; Gao, K; Kemp, DE, 2009) |
| "Side effects of carbamazepine (CBZ), valproate (VPA) and clonazepam (CZP) are rare during long-term use but rather common and usually transient during the early phases of treatment." | 1.27 | Side effects of carbamazepine, valproate and clonazepam during long-term treatment of epilepsy. ( Keränen, T; Sivenius, J, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (7.14) | 18.7374 |
| 1990's | 13 (23.21) | 18.2507 |
| 2000's | 18 (32.14) | 29.6817 |
| 2010's | 20 (35.71) | 24.3611 |
| 2020's | 1 (1.79) | 2.80 |
| Authors | Studies |
|---|---|
| Holder, SD | 1 |
| Tamburin, S | 1 |
| Faccini, M | 3 |
| Casari, R | 3 |
| Federico, A | 1 |
| Morbioli, L | 1 |
| Franchini, E | 1 |
| Bongiovanni, LG | 2 |
| Lugoboni, F | 3 |
| Das, S | 1 |
| Palappallil, DS | 1 |
| B C, M | 1 |
| Chatterjee, SS | 1 |
| Seredenina, T | 1 |
| Sorce, S | 1 |
| Herrmann, FR | 1 |
| Ma Mulone, XJ | 1 |
| Plastre, O | 1 |
| Aguzzi, A | 1 |
| Jaquet, V | 1 |
| Krause, KH | 1 |
| Cattaneo, CI | 1 |
| Ressico, F | 1 |
| Valsesia, R | 1 |
| D'Innella, P | 1 |
| Ballabio, M | 1 |
| Fornaro, M | 1 |
| Omar, M | 1 |
| Abdul, R | 1 |
| Panday, A | 1 |
| Teelucksingh, S | 1 |
| Pope, JD | 1 |
| Choy, KW | 1 |
| Drummer, OH | 1 |
| Schneider, HG | 1 |
| Coles, AS | 1 |
| Sasiadek, J | 1 |
| George, TP | 1 |
| Paino, M | 1 |
| Aletraris, L | 1 |
| Roman, PM | 1 |
| Uys, H | 1 |
| Janhsen, K | 1 |
| Roser, P | 1 |
| Hoffmann, K | 1 |
| Post, RM | 1 |
| Leverich, GS | 1 |
| Kupka, R | 1 |
| Keck, PE | 2 |
| McElroy, SL | 2 |
| Altshuler, LL | 1 |
| Frye, MA | 1 |
| Rowe, M | 1 |
| Grunze, H | 1 |
| Suppes, T | 2 |
| Nolen, WA | 1 |
| Dunsæd, F | 1 |
| Kristensen, Ø | 2 |
| Vederhus, JK | 2 |
| Clausen, T | 2 |
| Høie, MM | 1 |
| Kemp, DE | 6 |
| Gao, K | 6 |
| Ganocy, SJ | 6 |
| Caldes, E | 1 |
| Feldman, K | 1 |
| Chan, PK | 3 |
| Conroy, C | 4 |
| Bilali, S | 1 |
| Findling, RL | 6 |
| Calabrese, JR | 7 |
| Elhaj, O | 1 |
| Bilali, SR | 1 |
| Muzina, DJ | 1 |
| Xia, G | 1 |
| Deras, P | 1 |
| Gignon, L | 1 |
| Toumi, M | 1 |
| Louart, G | 1 |
| Muller, L | 1 |
| Boyer, JC | 1 |
| Lefrant, JY | 1 |
| Dikeos, D | 1 |
| Badr, MG | 1 |
| Yang, F | 1 |
| Pesek, MB | 1 |
| Fábián, Z | 1 |
| Tapia-Paniagua, G | 1 |
| Hudiţă, C | 1 |
| Okasha, T | 1 |
| D'yachkova, Y | 1 |
| Harrison, G | 1 |
| Treuer, T | 1 |
| Starer, J | 1 |
| Chang, G | 1 |
| Wang, Z | 2 |
| Serrano, MB | 2 |
| Sajatovic, M | 1 |
| Fang, Y | 1 |
| Albiero, A | 1 |
| Brigo, F | 1 |
| Quaglio, G | 2 |
| Storti, M | 1 |
| Fiaschi, A | 1 |
| Vigneau, CV | 1 |
| Mathewson, S | 1 |
| Licata, M | 1 |
| Holmes, LB | 1 |
| Suetsugu, S | 1 |
| Morita, N | 1 |
| Berigan, T | 1 |
| Myrick, H | 1 |
| Brady, KT | 4 |
| Bourgeois, JA | 1 |
| Koike, AK | 1 |
| Simmons, JE | 1 |
| Telles, S | 1 |
| Eggleston, C | 1 |
| Yatham, LN | 1 |
| Kennedy, SH | 1 |
| O'Donovan, C | 1 |
| Parikh, S | 1 |
| MacQueen, G | 1 |
| McIntyre, R | 1 |
| Sharma, V | 1 |
| Silverstone, P | 1 |
| Alda, M | 1 |
| Baruch, P | 1 |
| Beaulieu, S | 1 |
| Daigneault, A | 1 |
| Milev, R | 1 |
| Young, LT | 1 |
| Ravindran, A | 1 |
| Schaffer, A | 1 |
| Connolly, M | 1 |
| Gorman, CP | 1 |
| Lopez-Meza, E | 1 |
| Corona-Vazquez, T | 1 |
| Ruano-Calderon, LA | 1 |
| Ramirez-Bermudez, J | 1 |
| Saraga, M | 1 |
| Preisig, M | 1 |
| Zullino, DF | 1 |
| Rachid, F | 1 |
| Golaz, J | 1 |
| Bondolfi, G | 1 |
| Bertschy, G | 1 |
| Lølandsmo, T | 1 |
| Isaksen, A | 1 |
| Pedersen, B | 1 |
| Juul-Jensen, P | 1 |
| Keränen, T | 1 |
| Sivenius, J | 1 |
| Schmidt, A | 1 |
| Darius, J | 1 |
| Brosz, M | 1 |
| Roth, N | 1 |
| Meyer, FP | 1 |
| Kroker, S | 1 |
| Wien, F | 1 |
| Brett, B | 1 |
| Sonne, SC | 2 |
| Anton, R | 1 |
| Ballenger, JC | 1 |
| Bowden, CL | 2 |
| Roberts, JM | 1 |
| Malcolm, R | 2 |
| Santos, AB | 1 |
| Moore, JW | 1 |
| Kajdasz, DK | 1 |
| Cochrane, CE | 1 |
| Weiss, RD | 1 |
| Greenfield, SF | 1 |
| Najavits, LM | 1 |
| Soto, JA | 1 |
| Wyner, D | 1 |
| Tohen, M | 1 |
| Griffin, ML | 1 |
| Pages, KP | 1 |
| Ries, RK | 1 |
| Goldberg, JF | 1 |
| Garno, JL | 1 |
| Leon, AC | 1 |
| Kocsis, JH | 1 |
| Portera, L | 1 |
| Hertzman, M | 1 |
| Solhkhah, R | 1 |
| Finkel, J | 1 |
| Hird, S | 1 |
| Albanese, MJ | 1 |
| Clodfelter, RC | 1 |
| Khantzian, EJ | 1 |
| Shelton, MD | 1 |
| Rapport, DJ | 1 |
| Shirley, ER | 1 |
| Kimmel, SE | 1 |
| Caban, SJ | 1 |
| Cocchi, R | 1 |
| Tornati, A | 1 |
| Lawrence, JM | 1 |
| Apelt, S | 1 |
| Emrich, HM | 1 |
| Selten, JP | 1 |
| Ruser, I | 1 |
| Wason, S | 1 |
| Savitt, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PSG in Valproate-induced Nocturnal Enuresis in Children[NCT04191863] | 260 participants (Actual) | Observational | 2018-09-01 | Completed | |||
| A Randomized, Double Blind Comparison of Lithium Monotherapy Versus Lithium Plus Divalproex for the Outpatient Management of Hypomania/Mania in Patients With Rapid Cycling Bipolar Disorder Comorbid With Substance Abuse/Dependence[NCT00194129] | Phase 3 | 31 participants (Actual) | Interventional | 1997-11-30 | Completed | ||
| A Randomized, Double-blind, Double-dummy, Controlled Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide - a Pilot Study[NCT00400088] | Phase 3 | 2 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Recruitment difficulties) | ||
| Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression: Double-Blind, Placebo-Controlled Study to Establish Efficacy and Safety[NCT00590265] | 50 participants (Anticipated) | Interventional | 2008-01-31 | Active, not recruiting | |||
| Treatment of Polydrug-Using Opiate Dependents During Withdrawal[NCT00367874] | Phase 4 | 12 participants | Interventional | 2003-02-28 | Completed | ||
| A Randomised Trial on the Usefulness of Supportive Text Messages in the Treatment of Depressed Patients With Co-morbid Alcohol Dependency Syndrome[NCT01037868] | 56 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
| Dose Response Trial of Pergolide for Cocaine Dependence[NCT00000248] | Phase 3 | 0 participants | Interventional | 1996-02-29 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms[NCT00202514] | Phase 2/Phase 3 | 40 participants | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of subjects who no longer met criteria for active abuse or had entered into early full remission after receiving up to 6 months of open-label treatment with lithium and divalproex (NCT00194129)
Timeframe: Baseline to Month 6
| Intervention | Participants (Count of Participants) |
|---|---|
| Completers | 11 |
Number of subjects who no longer met criteria for active cannabis abuse or had entered into early full remission after receiving up to 6 months of open-label treatment with lithium and divalproex (NCT00194129)
Timeframe: Baseline to Month 6
| Intervention | Participants (Count of Participants) |
|---|---|
| Completers | 8 |
Number of subjects who no longer met criteria for active cocaine abuse or had entered into early full remission after receiving up to 6 months of open-label treatment with lithium and divalproex (NCT00194129)
Timeframe: Baseline to Month 6
| Intervention | Participants (Count of Participants) |
|---|---|
| Completers | 7 |
A relapse is a return to either a depressive, manic, hypomanic or mixed episode after a period of not have any symptoms. (NCT00194129)
Timeframe: Up to 6 months
| Intervention | weeks (Median) |
|---|---|
| Lithium Plus Divalproex | 17.8 |
| Lithium Plus Placebo | 15.9 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
12 reviews available for valproic acid and Substance-Related Disorders
| Article | Year |
|---|---|
Psychotic and Bipolar Disorders: Bipolar Disorder.
Topics: Antimanic Agents; Bipolar Disorder; Cardiovascular Diseases; Chronic Pain; Comorbidity; Family Pract | 2017 |
Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Carnitine; Humans; Hyperammonemia; Male; Substance-Relate | 2017 |
Pharmacotherapies for co-occurring substance use and bipolar disorders: A systematic review.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Humans; Lamo | 2019 |
The problems of long-term treatment with benzodiazepines and related substances.
Topics: Benzodiazepines; Carbamazepine; Flumazenil; Germany; Humans; Prevalence; Risk Factors; Substance Wit | 2015 |
Teratogen-induced limb defects.
Topics: Chorionic Villi Sampling; Female; Humans; Limb Deformities, Congenital; Male; Misoprostol; Phenytoin | 2002 |
[Organic solvent-related mental disorders].
Topics: Administration, Inhalation; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Haloperidol; Human | 2003 |
The use of divalproex in the treatment of addictive disorders.
Topics: Alcoholism; Antimanic Agents; Humans; Secondary Prevention; Substance Withdrawal Syndrome; Substance | 2003 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
The relationship between substance abuse and bipolar disorder.
Topics: Alcoholism; Bipolar Disorder; Carbamazepine; Comorbidity; Diagnosis, Dual (Psychiatry); Hospitalizat | 1995 |
Predictors of response to divalproex and lithium.
Topics: Bipolar Disorder; Carbamazepine; Comorbidity; Drug Administration Schedule; Drug Therapy, Combinatio | 1995 |
Use of anticonvulsants in benzodiazepine withdrawal.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Carbamazepine; Humans; Substance Withdrawal S | 1998 |
Bipolar rapid cycling: focus on depression as its hallmark.
Topics: Anticonvulsants; Antidepressive Agents, Tricyclic; Bipolar Disorder; Comorbidity; Controlled Clinica | 2001 |
9 trials available for valproic acid and Substance-Related Disorders
| Article | Year |
|---|---|
A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence.
Topics: Adolescent; Adult; Affect; Aged; Alcoholism; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Co | 2009 |
Predictors of non-stabilization during the combination therapy of lithium and divalproex in rapid cycling bipolar disorder: a post-hoc analysis of two studies.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Chi-Square Distribution; Comorbidity; Double-Blind Method | 2010 |
Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study.
Topics: Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Chi-Square Distribution; Depression | 2010 |
Treatment of polydrug-using opiate dependents during withdrawal: towards a standardisation of treatment.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Buprenorphine; Carbamazepine; Clonidi | 2006 |
Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study.
Topics: Acute Disease; Adult; Bipolar Disorder; Comorbidity; Diagnosis, Dual (Psychiatry); Female; Follow-Up | 1995 |
Pergolide mesylate. Adverse events occurring in the treatment of cocaine dependence.
Topics: Adult; Antimanic Agents; Cardiovascular Physiological Phenomena; Cardiovascular System; Cocaine; Dop | 1997 |
A history of substance abuse complicates remission from acute mania in bipolar disorder.
Topics: Acute Disease; Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Comorb | 1999 |
Divalproex sodium in substance abusers with mood disorder.
Topics: Adult; Anticonvulsants; Behavior, Addictive; Bipolar Disorder; Comorbidity; Depressive Disorder; Dru | 2000 |
[Clinical and experimental control of optimal therapy in epilepsy].
Topics: Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Epilepsy; Humans; Neurocognitive Disorder | 1990 |
35 other studies available for valproic acid and Substance-Related Disorders
| Article | Year |
|---|---|
Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Antidotes; Benzodiazepines; Female; Flumaze | 2017 |
Chlorpheniramine dependence presenting as mania.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Chlorpheniramine; Diagnosis, Differential; GABA Agent | 2017 |
Decreased NOX2 expression in the brain of patients with bipolar disorder: association with valproic acid prescription and substance abuse.
Topics: Adult; Bipolar Disorder; Brain; Female; Gyrus Cinguli; Humans; Male; Microglia; Middle Aged; NADPH O | 2017 |
Anabolic steroid abuse: what shall it profit a man to gain muscle and suffer the loss of his brain?
Topics: Acute Disease; Adult; Anabolic Agents; Heparin; Humans; Magnetic Resonance Imaging; Male; Nandrolone | 2017 |
Harmala Alkaloids Identify Ayahausca Intoxication in a Urine Drug Screen.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Banisteriopsis; Chromatography, Liquid; Hallucinogens | 2019 |
The use of off-label medications in substance abuse treatment programs.
Topics: Accreditation; Adrenergic alpha-2 Receptor Agonists; Anticonvulsants; Antiemetics; Baclofen; Clonidi | 2020 |
Prevalence and clinical presentation of HIV positive female psychiatric inpatients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Cross-Sectional Studie | 2013 |
Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disor | 2016 |
Standardised detoxification in cases of polydrug use.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Anticonvulsants; Clonidine; Cohort St | 2016 |
Medical and substance use comorbidity in bipolar disorder.
Topics: Adult; Affect; Aging; Antimanic Agents; Bipolar Disorder; Comorbidity; Drug Resistance; Drug Therapy | 2009 |
Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder.
Topics: Adult; Affect; Anticonvulsants; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar | 2008 |
[Lactic acidosis after voluntary intoxication with valproic acid].
Topics: Acidosis, Lactic; Acute Kidney Injury; Adult; Combined Modality Therapy; Depressive Disorder; Emerge | 2010 |
Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Comorbidity; Diagnostic and Statisti | 2010 |
Hyperammoneic encephalopathy, valproic acid, and benzodiazepine withdrawal: a case series.
Topics: Benzodiazepines; Brain Diseases, Metabolic; Drug Administration Schedule; Female; GABA Agents; Human | 2010 |
Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome.
Topics: Adult; Bipolar Disorder; Body Mass Index; Comorbidity; Endocrine System Diseases; Female; Humans; Li | 2010 |
Focal nonconvulsive seizures during detoxification for benzodiazepine abuse.
Topics: Adult; Anticonvulsants; Benzodiazepines; Female; Flumazenil; GABA Modulators; Humans; Infusions, Int | 2012 |
Megadose bromazepam and zolpidem dependence: two case reports of treatment with flumazenil and valproate.
Topics: Adult; Anticonvulsants; Bromazepam; Female; Flumazenil; GABA Modulators; GABA-A Receptor Agonists; H | 2012 |
Modafinil treatment of excessive sedation associated with divalproex sodium.
Topics: Adult; Antimanic Agents; Benzhydryl Compounds; Bipolar Disorder; Central Nervous System Stimulants; | 2004 |
Adjunctive valproic acid for delirium and/or agitation on a consultation-liaison service: a report of six cases.
Topics: Alcohol Withdrawal Delirium; Alcoholism; Anticonvulsants; Delirium; Fever; Humans; Injections, Intra | 2005 |
Severe impulsiveness as the primary manifestation of multiple sclerosis in a young female.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Child; Clozapine; Female; Homicide; Human | 2005 |
Reduced valproate plasma levels possible after introduction of efavirenz in a bipolar patient.
Topics: Adult; Alkynes; Anti-HIV Agents; Anticonvulsants; Benzoxazines; Bipolar Disorder; Cyclopropanes; Dos | 2006 |
Induction of a mixed depressive episode during rTMS treatment in a patient with refractory major depression.
Topics: Adult; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive | 2006 |
Electroencephalographic alterations during intoxication with sodium valproate: a case report.
Topics: Adult; Coma; Electroencephalography; Female; Humans; Renal Dialysis; Respiration Disorders; Substanc | 1984 |
Side effects of carbamazepine, valproate and clonazepam during long-term treatment of epilepsy.
Topics: Abnormalities, Drug-Induced; Arousal; Benzodiazepinones; Carbamazepine; Chemical and Drug Induced Li | 1983 |
[The effect of valproic acid monotherapy on behavior and cognitive performance of children with idiopathic generalized epilepsy].
Topics: Adolescent; Anticonvulsants; Child; Child Behavior Disorders; Dose-Response Relationship, Drug; Elec | 1995 |
Treatment of panic disorder and comorbid substance abuse with divalproex sodium.
Topics: Adult; Alprazolam; Comorbidity; Humans; Male; Panic Disorder; Substance-Related Disorders; Treatment | 1994 |
Medication compliance among patients with bipolar disorder and substance use disorder.
Topics: Adult; Benzodiazepines; Bipolar Disorder; Carbamazepine; Comorbidity; Female; Humans; Lithium; Male; | 1998 |
Divalproex sodium to treat concomitant substance abuse and mood disorders.
Topics: Adolescent; Adult; Alcoholism; Bipolar Disorder; Comorbidity; Female; Humans; Male; Middle Aged; Moo | 2000 |
Possible risperidone-induced visual hallucinations.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diagnosis, Du | 2000 |
Difficulties in diagnosis and management of bipolar disorder: three case presentations.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Combined Modality The | 2000 |
[Psychological dependence? A possible different formulation of the problem for a therapeutic rearrangement in chronic drug addictions].
Topics: Antidepressive Agents; gamma-Aminobutyric Acid; Glutamine; Humans; Piracetam; Substance-Related Diso | 1977 |
Treatment of panic disorder and benzodiazepine withdrawal with valproate.
Topics: Adult; Agoraphobia; Clonazepam; Diazepam; Dose-Response Relationship, Drug; Humans; Male; Panic Diso | 1991 |
Sodium valproate in benzodiazepine withdrawal.
Topics: Adult; Benzodiazepines; Female; Humans; Male; Substance Withdrawal Syndrome; Substance-Related Disor | 1990 |
[Valproic acid and stupor].
Topics: Cognition Disorders; Humans; Substance-Related Disorders; Valproic Acid | 1990 |
Acute valproic acid toxicity at therapeutic concentrations.
Topics: Child; Cognition Disorders; Confusion; Female; Humans; Substance-Related Disorders; Valproic Acid | 1985 |